HLS Therapeutics to Present at the Stifel Healthcare Conference

TORONTO, Nov. 14, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, CEO, and Tim Hendrickson, CFO, will take part in a fireside chat with Stifel Healthcare analyst, Justin Keywood, at the 2022 Stifel Healthcare Conference on Wednesday November 16, 2022 at 8:35 a.m. Eastern Time. The conference is being held at the Lotte New York Palace Hotel in New York City.

The Company's fireside chat will be webcast at: https://wsw.com/webcast/stifel74/hls.to/2368752 

HLS will also host one-on-one meetings with investors at the conference. To request a one-on-one meeting, please contact your Stifel representative.

ABOUT HLS THERAPEUTICS INC.

Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information, please visit: www.hlstherapeutics.com

SOURCE HLS Therapeutics Inc.

HLS CONTACT INFORMATION: Dave Mason, Investor Relations, HLS Therapeutics Inc., [phone], [email protected]